赛诺菲-安万特 SNY 深 沪
等待开盘 06-26 09:30:00 美东时间
41.77
+0.440
+1.06%
华盛通- 最 高42.47
- 今 开41.50
- 成交量 425.10万股
- 最 低 40.89
- 昨 收 41.33
- 总市值 1.06亿
- 52周最高 52.68
- 市盈率 静 14.29
- 换手率 168.22%
- 52周最低 40.89
- 委 比 58.38%
- 总股本 0.03亿
- 历史最高 60.115
- 量 比 0.60
- 振 幅 3.82%
- 历史最低 1.10
- 每 手 1
- 风险率 2.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection
Sanofi won European approval for Cenrifki in SPMS and secured Japan authorization for Wayrilz in chronic ITP.
06-24 00:21
AbbVie Expands Immunology Footprint With Apogee $11 Billion Acquisition
AbbVie will acquire Apogee for $10.9 billion, adding late-stage immunology and asthma assets to its pipeline.
06-22 21:15
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients
FDA grants accelerated approval to Sanofi Tzield for children with newly diagnosed stage 3 type 1 diabetes, backed by Phase 3 data.
06-16 01:15
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Sanofi discontinues Phase 3 riliprubart study for CIDP due to low efficacy. SNY stock ticks up. Read the market & analyst reaction.
06-11 21:09
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative
Owkin and Sanofi expand their AI partnership with a five-year deal to develop agentic systems aimed at accelerating drug research.
06-05 19:01
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron beats Q1 estimates as Eylea HD demand rises, while margins narrow and FDA decisions on manufacturing remain pending.
04-30 01:57
FDA Approval Broadens Dupixent Use While Sanofi Posts Earnings Beat
Sanofi, Regeneron win FDA nod for Dupixent in pediatric CSU as Q1 sales beat estimates, driven by strong Dupixent growth.
04-23 23:02
Earnings Scheduled For April 23, 2026
Companies Reporting Before The Bell • Popular (NASDAQ:BPOP) is estimated to rep...
04-23 19:11
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
04-23 02:20
Sanofi Eyes First On-Body Injector Cancer Therapy As FDA Delays Decision
Sanofi says FDA delays Sarclisa SC review to July while expanding Tzield use to younger children with type 1 diabetes.
04-22 19:35
